Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Антиишемический эффект длительного применения Кораксана у пациентов с ишемической болезнью сердца и сахарным диабетом в амбулаторной практике
Антиишемический эффект длительного применения Кораксана у пациентов с ишемической болезнью сердца и сахарным диабетом в амбулаторной практике
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Проанализированы результаты использования в амбулаторной практике ингибитора f-каналов ивабрадина (Кораксана) у пациентов с ишемической болезнью сердца и сахарным диабетом. Показано, что включение Кораксана в состав комплексной терапии у пациентов данной группы приводит к статистически значимому снижению частоты и длительности приступов стенокардии и способствует осуществлению более адекватного контроля ритма сердца при максимальных физических нагрузках, и особенно в ночное время.
Ключевые слова: ишемическая болезнь сердца, сахарный диабет, b-блокаторы, ингибиторы f-каналов (Кораксан).
Key words: coronary heart disease, diabetes mellitus, b-blockers, f-channel inhibitors (Coraxan).
Ключевые слова: ишемическая болезнь сердца, сахарный диабет, b-блокаторы, ингибиторы f-каналов (Кораксан).
________________________________________________
Key words: coronary heart disease, diabetes mellitus, b-blockers, f-channel inhibitors (Coraxan).
Полный текст
Список литературы
1. Kempler P. Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Springer, 2002.
2. Aaron IV, Raelene EM, Braxton DM et al. Diabetic Autonomic Neuropathy, Diabetes Care 2003; 26: 1553–79.
3. Vinik AI. Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999; 107: 17S–26S.
4. Niakan E, Harati Y, Rolak LA et al. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986; 146: 2229–30.
5. Hume L, Oakley GD, Boulton AJ et al. Asymptomatic myocardial ischemia in diabetes and its relationship to diabetic neuropathy: an exercise electrocardiography study in middle-aged diabetic men. Diabetes Care 1986; 384–8.
6. Murray DP, O’Brien T, Mulrooney R. Autonomic dysfunction and silent myocardial ischaemia on exercise testing in diabetes mellitus. Diabet Med 1990; 7: 580–4.
7. Langer A, Freeman MR, Josse RG et al. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 1991; 67: 1073–8.
8. O’Sullivan JJ, Conroy RM, MacDonald K et al. Silent ischemia in diabetic men with autonomic neuropathy. Br Heart J 1991; 66: 313–5.
9. Koistinen MJ, Airaksinen KE, Huikuri HV et al. Asymptomatic coronary artery disease in diabetes: associated with autonomic neuropathy? Acta Diabetol 1992; 28: 199–202.
10. Hartmann A, Schlottog B, Jungmann E et al. Somatic pain threshold and reactive hyperemia in autonomic diabetic neuropathy and silent myocardial ischemia. Int J Cardiol 1991; 42: 121–73.
11. Jermendy G, Davidovits Z, Khoor S. Silent coronary artery disease in diabetic patients with cardiac autonomic neuropathy. Diabetes Care 1994; 17: 1231–2.
12. Zarich S, Waxman S, Freeman RT et al. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol 1994; 24: 956–62.
13. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol 1997; 79: 134–9.
14. Jalal S, Alai MS, Khan KA et al. Silent myocardial ischemia and cardiac autonomic neuropathy in diabetics. J Assoc Physicians India 1999; 47: 767–9.
15. Valensi P, Sachs RN, Harfouche B et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001; 24: 339–43.
16. Haiat R, Leroy G. Cardiovascular therapeutics: cross–sectional analysis of major clinical trials. Paris: Editions Frison–Roche, 1999.
17. Pepine CJ, Cohn PF, Deedwania PC et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent ischemia Study (ASIST). Сirculation 1994; 90: 762–8.
18. Widimsky J, Kremer HJ, Jerie P, Uhlir O. A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. (CASSIS). Eur J Clin Pharmacol 1995; 49: 95–102.
19. Amim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total ischemic Burden Bisoprolol Study (TIBBS) follow-up. J Am Coll Cardiol 1996; 28: 20–4.
20. Dargie HJ, Ford I, Fox KM. Total ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17: 104–12.
21.The Beta-Blocker Pooling Project Research Group. The Beta- Blocker Pooling Project (BBPP): subgroup findings from randomized trails in post infarction patients. Eur Heart J 1988; 9: 8–16.
22. Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваск. тер. и профилакт. 2004; 3 (3). ч. 1: 10–4.
23. Braman N. Singh. Morbidity in Cardiovascular Disorders; Impact of Reduced Heart Rate. J Cardiovasc Pharmacol Ther 2001; 6: 4: 313–31.
24. Di Francesco D, Camm A. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004; 64 (16): 1757–65.
25. Kjekshus J. Importance of heart rate in determing beta-blocker efficacy in acute and long-term miokardial infarction intervention trials. Am J Cardiol 1986; 57: 43F–9.
26. Kjekshus J, Gilpin E, Blackey AR et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11: 43–50.
27. Sawicki PT, Siebenhofer A. Beta-bloker treatment in diabetes mellitus. J Intern Med 2001; 250: 11–7.
28. Poople-Wilson PA, Swedberg K, Cleland JG et al. for the COMET Investigators. Comparison of carvedilol or metoprolol in the Carvedilol European Trial (Comet): randomized Controlled trial. Lancet 2003; 362: 7–13.
29. Malmberg K, Herlitz J, Hjalmarson A, Ruden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infraction. Retrospective data from two large scale studies. Eur Heart J 1989; 10: 423–8.
30. Haas SJ, Vos T, Gilbert RE, Krum H. Are B-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure: A meta-analusis of large-scale clinical trials. Am Heart J 2003; 146: 848–53.
31. Management of stable angina pectoris. recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394–413.
32. Williams SV, Fihn SD, Gibbons RJ et al. Guidelines for the management of patients with chronic stable angina: diagnosis and risk stratification. Ann Intern Med 2001; 135: 530–47.
33. Monnet X, Ghaleh B, Colin P et al. Effects of heart rate reduction with ivabradine on exercise induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001; 284: 1133–9.
34. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008. DOI: 10.1016 /S0140-6736 (08) 61170-8.
35. Reil JC, Bohm M. BEAUTIFUL results-the slower, the better? Lancet 2008. DOI: 10.1016/ S0140–6736 (08) 61172-1.
36. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008. DOI:10.1016/ S0140–6736(08) 61171-X.
37. Жаров Е.И., Казанков Ю.Н., Лагуткин Д.И. Безболевая ишемия миокарда у больных сахарным диабетом и ишемической болезнью сердца. Кардиология. 1993; 8: 73–7.
38. Кондратьев В.В., Бочкарева Е.В., Кокурина Е.В. Безболевая ишемия миокарда. Современное состояние проблемы и клинически значимые аспекты ее развития. II. Механизмы формирования безболевой ишемии миокарда. Кардиология. 1997; 2: 90–5.
39. Фомин И.В., Валикулова Ф.Ю. Антиангинальный эффект длительного применения Ивабрадина у больных ИБС и СД в условиях амбулаторной практики. Кардиология. 2009; 3: 5–15.
2. Aaron IV, Raelene EM, Braxton DM et al. Diabetic Autonomic Neuropathy, Diabetes Care 2003; 26: 1553–79.
3. Vinik AI. Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999; 107: 17S–26S.
4. Niakan E, Harati Y, Rolak LA et al. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986; 146: 2229–30.
5. Hume L, Oakley GD, Boulton AJ et al. Asymptomatic myocardial ischemia in diabetes and its relationship to diabetic neuropathy: an exercise electrocardiography study in middle-aged diabetic men. Diabetes Care 1986; 384–8.
6. Murray DP, O’Brien T, Mulrooney R. Autonomic dysfunction and silent myocardial ischaemia on exercise testing in diabetes mellitus. Diabet Med 1990; 7: 580–4.
7. Langer A, Freeman MR, Josse RG et al. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 1991; 67: 1073–8.
8. O’Sullivan JJ, Conroy RM, MacDonald K et al. Silent ischemia in diabetic men with autonomic neuropathy. Br Heart J 1991; 66: 313–5.
9. Koistinen MJ, Airaksinen KE, Huikuri HV et al. Asymptomatic coronary artery disease in diabetes: associated with autonomic neuropathy? Acta Diabetol 1992; 28: 199–202.
10. Hartmann A, Schlottog B, Jungmann E et al. Somatic pain threshold and reactive hyperemia in autonomic diabetic neuropathy and silent myocardial ischemia. Int J Cardiol 1991; 42: 121–73.
11. Jermendy G, Davidovits Z, Khoor S. Silent coronary artery disease in diabetic patients with cardiac autonomic neuropathy. Diabetes Care 1994; 17: 1231–2.
12. Zarich S, Waxman S, Freeman RT et al. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol 1994; 24: 956–62.
13. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol 1997; 79: 134–9.
14. Jalal S, Alai MS, Khan KA et al. Silent myocardial ischemia and cardiac autonomic neuropathy in diabetics. J Assoc Physicians India 1999; 47: 767–9.
15. Valensi P, Sachs RN, Harfouche B et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001; 24: 339–43.
16. Haiat R, Leroy G. Cardiovascular therapeutics: cross–sectional analysis of major clinical trials. Paris: Editions Frison–Roche, 1999.
17. Pepine CJ, Cohn PF, Deedwania PC et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent ischemia Study (ASIST). Сirculation 1994; 90: 762–8.
18. Widimsky J, Kremer HJ, Jerie P, Uhlir O. A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. (CASSIS). Eur J Clin Pharmacol 1995; 49: 95–102.
19. Amim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total ischemic Burden Bisoprolol Study (TIBBS) follow-up. J Am Coll Cardiol 1996; 28: 20–4.
20. Dargie HJ, Ford I, Fox KM. Total ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17: 104–12.
21.The Beta-Blocker Pooling Project Research Group. The Beta- Blocker Pooling Project (BBPP): subgroup findings from randomized trails in post infarction patients. Eur Heart J 1988; 9: 8–16.
22. Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваск. тер. и профилакт. 2004; 3 (3). ч. 1: 10–4.
23. Braman N. Singh. Morbidity in Cardiovascular Disorders; Impact of Reduced Heart Rate. J Cardiovasc Pharmacol Ther 2001; 6: 4: 313–31.
24. Di Francesco D, Camm A. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004; 64 (16): 1757–65.
25. Kjekshus J. Importance of heart rate in determing beta-blocker efficacy in acute and long-term miokardial infarction intervention trials. Am J Cardiol 1986; 57: 43F–9.
26. Kjekshus J, Gilpin E, Blackey AR et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11: 43–50.
27. Sawicki PT, Siebenhofer A. Beta-bloker treatment in diabetes mellitus. J Intern Med 2001; 250: 11–7.
28. Poople-Wilson PA, Swedberg K, Cleland JG et al. for the COMET Investigators. Comparison of carvedilol or metoprolol in the Carvedilol European Trial (Comet): randomized Controlled trial. Lancet 2003; 362: 7–13.
29. Malmberg K, Herlitz J, Hjalmarson A, Ruden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infraction. Retrospective data from two large scale studies. Eur Heart J 1989; 10: 423–8.
30. Haas SJ, Vos T, Gilbert RE, Krum H. Are B-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure: A meta-analusis of large-scale clinical trials. Am Heart J 2003; 146: 848–53.
31. Management of stable angina pectoris. recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394–413.
32. Williams SV, Fihn SD, Gibbons RJ et al. Guidelines for the management of patients with chronic stable angina: diagnosis and risk stratification. Ann Intern Med 2001; 135: 530–47.
33. Monnet X, Ghaleh B, Colin P et al. Effects of heart rate reduction with ivabradine on exercise induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001; 284: 1133–9.
34. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008. DOI: 10.1016 /S0140-6736 (08) 61170-8.
35. Reil JC, Bohm M. BEAUTIFUL results-the slower, the better? Lancet 2008. DOI: 10.1016/ S0140–6736 (08) 61172-1.
36. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008. DOI:10.1016/ S0140–6736(08) 61171-X.
37. Жаров Е.И., Казанков Ю.Н., Лагуткин Д.И. Безболевая ишемия миокарда у больных сахарным диабетом и ишемической болезнью сердца. Кардиология. 1993; 8: 73–7.
38. Кондратьев В.В., Бочкарева Е.В., Кокурина Е.В. Безболевая ишемия миокарда. Современное состояние проблемы и клинически значимые аспекты ее развития. II. Механизмы формирования безболевой ишемии миокарда. Кардиология. 1997; 2: 90–5.
39. Фомин И.В., Валикулова Ф.Ю. Антиангинальный эффект длительного применения Ивабрадина у больных ИБС и СД в условиях амбулаторной практики. Кардиология. 2009; 3: 5–15.
Авторы
Ф.Ю.Валикулова, И.В.Фомин, Д.И.Абелевич
ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава РФ
Nizhny State Medical Academy, Ministry of Health and Social Development of the Russian Federation
ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава РФ
________________________________________________
Nizhny State Medical Academy, Ministry of Health and Social Development of the Russian Federation
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.